NLRP3 and severe acute respiratory syndrome: When tested in the context of SARS-CoV infection, treatments targeting NLRP3 pathway components including NF-κB, inflammatory macrophages, and IFN-I all demonstrated significant efficacy despite unchanged viral titers their respective human, murine, macaque, and/or in vitro models (5, 35, 106, 107, 196).